BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells

Chemical Compounds

• Ponatinib 100%
• Tyrosine 94%
• Nilotinib 90%
• Metabolic 83%
• Tumorigenic 77%
• Imatinib 76%
• Apoptosis Induction 75%
• Oncogenic 72%
• Tyrosine Kinase Inhibitor 71%
• Phosphoinositide 70%
• Nutrient 54%
• Protein 42%

Medicine & Life Sciences

• Protein-Tyrosine Kinases 93%
• Phosphotransferases 79%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65%
• Physiological Stress 49%
• Endoplasmic Reticulum 39%
• Protein Kinases 38%
• ponatinib 34%
• Activating Transcription Factor 4 31%
• Eukaryotic Initiation Factor-2 31%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 29%
• Dasatinib 28%
• Pharmacology 27%
• Proteostasis 26%
• K562 Cells 24%
• Imatinib Mesylate 23%
• TOR Serine-Threonine Kinases 22%
• Myeloid Cells 21%
• Phosphatidylinositol 3-Kinase 20%
• Nutrients 17%
• Apoptosis 12%
• Neoplasms 6%